MTD Group (parent company of HTL-Strefa, Inc) completes the acquisition of Ypsomed’s Pen Needles and Blood Glucose Monitoring Systems and announces a significant investment plan for its European production sites
Published on August 2, 2024
Medical Technology and Devices (MTD; www.mtdglobal.com ) is pleased to announce the successful closing of the acquisition of Ypsomed's Pen Needles and Blood Glucose Monitoring Systems (BGM) businesses, a strategic acquisition initially announced at the end of March. This acquisition marks a major step forward in MTD's...
Read More